TrialEndocrinology, diabetes & metabolism2022

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.

Pierre Theurey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.